Products for Research Use Only

MRT68921

CAT: 0804-HY-100006-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100006-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MRT68921 is a potent NUAK1/ULK1 dual inhibitor. MRT68921 inhibits ULK1 and ULK2 with IC50 values of 2.9 nM and 1.1 nM, respectively. MRT68921 can block cells autophagy and kill tumor cells by breaking the balance of oxidative stress signals. MRT68921 can inhibit cell proliferation and induce ROS production and apoptosis. MRT68921 can be used for the research of cancer, such as breast cancer[1][2].
CAS Number
1190379-70-4
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
Apoptosis; Bcl-2 Family; GSK-3; Reactive Oxygen Species (ROS) ; ULK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MRT68921.html
Purity
99.71
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1CCC1)NCCCNC2=NC(NC3=CC4=C(CN(C)CC4)C=C3)=NC=C2C5CC5
Molecular Formula
C25H34N6O
Molecular Weight
434.58
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Petherick KJ, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR) -dependent autophagy. J Biol Chem. 2015 May 1;290 (18) :11376-83.|[2]Chen Y, et al. Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities. Cell Death Dis. 2020 Sep 1;11 (8) :712.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-2; GSK-3β; ULK1; ULK2
Citation 01
ACS Nano. 2024 Jul 2;18 (26) :16790-16807.|bioRxiv. 2025 Jun 5:2025.05.29.656904.|Dev Cell. 2025 Jun 27:S1534-5807 (25) 00372-7.|J Ethnopharmacol. 2024 Aug 3:118658.|Mol Med Rep. 2024 Apr;29 (4) :67.|Mol Ther Oncolytics. 2021 Aug 28:23:107-123.|mSphere. 2025 Jan 10:e0053724.|Nat Commun. 2025 Nov 19;16 (1) :10181.|Patent. US20230068698A1.|PLoS Pathog. 2024 Aug 13;20 (8) :e1012461.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 May 22.|SSRN. 2025 Jul 25.|Biochem J. 2019 Mar 12;476 (5) :875-887.|Bioorg Chem. 2024 Jun:147:107412.|Cancer Cell. 2021 May 10;39 (5) :678-693.e11.|Dev Cell. 2024 Jan 22;59 (2) :228-243.e7.|J Cell Physiol. 2021 Dec;236 (12) :8110-8121.|Medical University of South Carolina. 2023 Aug 12.|Nature Cancer. 2021 May;2 (5) :503-514.|Nature. 2022 Oct;610 (7931) :366-372.|Patent. US20230068698A1.|Res Sq. 2025 May 07.|Sci Rep. 2023 Jul 3;13 (1) :10752.

Popular Products